Literature DB >> 19006450

Topical microbicides to prevent HIV: clinical drug development challenges.

Craig W Hendrix1, Ying Jun Cao, Edward J Fuchs.   

Abstract

Microbicides, substances applied topically to prevent sexual HIV infection, are needed to empower receptive sexual partners with effective prevention methods. Several large microbicide trials, however, failed to demonstrate efficacy, thus motivating a reevaluation of the current microbicide development paradigm, which has been largely empirically based. Microbicide use occurs in a highly complex environment involving multi-level interactions, behavioral and biochemical, among host, virus, and drug, yet many details of these interactions remain unknown. Fundamental information regarding virus and drug distribution over time in sexually receptive body compartments that is necessary to design a microbicide able to outdistance and outlast the virus is largely absent. Recent efforts have been made to establish a simple conceptual framework for obtaining the knowledge that is likely to inform a more mechanistic, model-based development paradigm. These efforts have also advanced the development of numerous methodological approaches to obtain the knowledge needed to improve microbicide development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19006450     DOI: 10.1146/annurev.pharmtox.48.113006.094906

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  42 in total

1.  Submicron Matrices Embedded in a Polymeric Caplet for Extended Intravaginal Delivery of Zidovudine.

Authors:  Felix Mashingaidze; Yahya E Choonara; Pradeep Kumar; Lisa C du Toit; Vinesh Maharaj; Eckhart Buchmann; Viness Pillay
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

2.  Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men.

Authors:  Nicolette A Louissaint; Sridhar Nimmagadda; Edward J Fuchs; Rahul P Bakshi; Ying-Jun Cao; Linda A Lee; Jeff Goldsmith; Brian S Caffo; Yong Du; Karen E King; Frederick A Menendez; Michael S Torbenson; Craig W Hendrix
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

3.  Design of a semisolid vaginal microbicide gel by relating composition to properties and performance.

Authors:  Alamelu Mahalingam; Eric Smith; Judit Fabian; Festo R Damian; Jennifer J Peters; Meredith R Clark; David R Friend; David F Katz; Patrick F Kiser
Journal:  Pharm Res       Date:  2010-09-15       Impact factor: 4.200

Review 4.  Vaginal drug distribution modeling.

Authors:  David F Katz; Andrew Yuan; Yajing Gao
Journal:  Adv Drug Deliv Rev       Date:  2015-04-28       Impact factor: 15.470

5.  Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention.

Authors:  Heather A Pines; Pamina M Gorbach; Cathy J Reback; Raphael J Landovitz; Matt G Mutchler; Ronald Mitsuyasu
Journal:  AIDS Care       Date:  2014-07-15

6.  Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.

Authors:  R Karl Malcolm; Claire J Forbes; Leslie Geer; Ronald S Veazey; Laurie Goldman; Per Johan Klasse; John P Moore
Journal:  J Antimicrob Chemother       Date:  2012-10-30       Impact factor: 5.790

7.  Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.

Authors:  Nicola Richardson-Harman; Christine Mauck; Ian McGowan; Peter Anton
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-20       Impact factor: 2.205

8.  An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.

Authors:  Marc M Baum; Irina Butkyavichene; Scott A Churchman; Gilbert Lopez; Christine S Miller; Thomas J Smith; John A Moss
Journal:  Int J Pharm       Date:  2015-09-16       Impact factor: 5.875

9.  Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Authors:  R DiFrancesco; K Tooley; S L Rosenkranz; S Siminski; C R Taylor; P Pande; G D Morse
Journal:  Clin Pharmacol Ther       Date:  2013-03-26       Impact factor: 6.875

10.  Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.

Authors:  John A Moss; Priya Srinivasan; Thomas J Smith; Irina Butkyavichene; Gilbert Lopez; Amanda A Brooks; Amy Martin; Chuong T Dinh; James M Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.